Lebrikizumab

證據等級: L5

預測適應症: 10 個

Lebrikizumab: From [Indication Not on Record] to Severe Nonproliferative Diabetic Retinopathy

One-Sentence Summary

Lebrikizumab is a monoclonal antibody that selectively inhibits interleukin-13 (IL-13); no approved original indication is on record in this evidence pack, and the drug is not marketed in Taiwan. The TxGNN model’s top-ranked prediction is Severe Nonproliferative Diabetic Retinopathy (score 97.94%), but this candidate has 0 clinical trials and 0 publications supporting it — the model’s own rationale states the score likely reflects structural similarity to other anti-inflammatory biologics in the knowledge graph rather than a real mechanistic signal.

Quick Overview

Item	Content
Original Indication	Not available — no approved indication on record (`original_indications` empty; not marketed in Taiwan)
Predicted New Indication	Severe Nonproliferative Diabetic Retinopathy
TxGNN Prediction Score	97.94%
Evidence Level	L5
Market Status (TFDA)	未上市 (Not marketed)
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for Lebrikizumab in this evidence pack (flagged as a High-severity data gap). Based on information embedded elsewhere in the pack, Lebrikizumab is a high-affinity IgG4 monoclonal antibody that selectively binds and neutralizes IL-13, blocking the IL-4Rα/IL-13Rα1 signaling complex — a mechanism well documented in the evidence collected for other candidate indications in this pack (notably dermatitis, rank #5).

For this specific top-ranked prediction, however, the pack’s own repurposing rationale is explicit and skeptical: “There is no evidence supporting a relationship between IL-13 inhibition and the progression of diabetic retinopathy. The high TxGNN score likely arises from structural similarity in the knowledge graph to other anti-inflammatory biologics, rather than genuine mechanistic or clinical evidence.”

IL-13-driven Th2 inflammation is not an established pathway in diabetic retinal microvascular disease, which is instead driven primarily by hyperglycemia-induced VEGF signaling, oxidative stress, and vascular permeability changes. No preclinical, observational, or clinical data in this pack bridge that gap. This prediction should be treated as a pure knowledge-graph score, not a mechanistically grounded hypothesis.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

US Market Information

Lebrikizumab is not marketed in Taiwan (0 licenses on record); no authorization data is available.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction is supported only by a TxGNN model score with no corroborating clinical trials, literature, or plausible mechanistic link — evidence level L5, decision stage S0. The rationale text accompanying this prediction directly questions its own validity, attributing the score to structural artifacts in the knowledge graph rather than a real biological signal.

To proceed, the following is needed:

Confirmed original indication and MOA data (currently marked Blocking/High-severity data gaps — TFDA label and DrugBank MOA lookup)
Preclinical or mechanistic studies establishing any link between IL-13 inhibition and diabetic retinal microvascular disease
Re-evaluation against lower-ranked candidates in this same evidence pack that have substantially stronger support: dermatitis (rank #5 — 29 trials, 20 publications, multiple completed Phase 3 RCTs) reflects the drug’s well-established IL-13 biology, and psoriasis (rank #9 — L4, decision stage S1, “Research Question”) has partial mechanistic and literature support worth independent follow-up.
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.